Skip Navigation


Brain Advance Access originally published online on August 22, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
126/11/2497    most recent
awg254v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by O’Hanlon, G. M.
Right arrow Articles by Willison, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Hanlon, G. M.
Right arrow Articles by Willison, H. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 126, No. 11, 2497-2509, November 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg254

Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury

Graham M. O’Hanlon1, Peter D. Humphreys1, Rebecca S. Goldman1, Susan K. Halstead1, Roland W. M. Bullens3,4, Jaap J. Plomp3,4, Yuri Ushkaryov2 and Hugh J. Willison1

1 University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, 2 Department of Biological Sciences, Imperial College, London, UK and 3 Departments of Neurophysiology and 4 Neurology, Leiden University Medical Centre, The Netherlands

Correspondence to: Hugh J. Willison, Division of Clinical Neurosciences, University of Glasgow Department of Neurology, Southern General Hospital, Glasgow G51 4TF, UK E-mail: h.j.willison{at}udcf.gla.ac.uk

Miller Fisher syndrome-associated anti-GQ1b ganglioside antibodies produce an acute complement-dependent neuroexocytic effect at the mouse neuromuscular junction (NMJ) that closely resembles the effect of {alpha}-latrotoxin (LTx). This pathophysiological effect is accompanied by morphological disruption of the nerve terminal involving the loss of major cytoskeletal components, including neurofilament. Both LTx and the membrane attack complex of complement form membrane pores that allow free ionic movement and we have previously hypothesized that Ca2+ ingress and the subsequent activation of Ca2+-dependent proteases, calpains, may lead to substrate degradation resulting in structural disorganization of the terminal. Here, we treated mouse NMJs in hemidiaphragm preparations with anti-GQ1b antibodies and complement, or with LTx in the presence and absence of extracellular Ca2+, and studied possible neuroprotective effects of the calpain inhibitors calpeptin and calpain inhibitor V. Both Ca2+ depletion and calpain inhibition protected the cytoskeleton from degradation, as assessed by immunohistological and ultrastructural analysis. Calpain inhibitors may therefore be useful therapeutically in limiting nerve terminal and axonal injury in autoimmune peripheral neuropathy and in human latrodectism.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung
Review: Pathogenesis and treatment of immune-mediated neuropathies
Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281.
[Abstract] [PDF]

Home page
 GlycobiologyHome page
K. Kaida, T. Ariga, and R. K Yu
Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A review
Glycobiology, July 1, 2009; 19(7): 676 - 692.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. Lonigro and J. J. Devaux
Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis
Brain, January 1, 2009; 132(1): 260 - 273.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
V. Ramaglia, R. H. M. King, M. Nourallah, R. Wolterman, R. de Jonge, M. Ramkema, M. A. Vigar, S. van der Wetering, B. P. Morgan, D. Troost, et al.
The Membrane Attack Complex of the Complement System Is Essential for Rapid Wallerian Degeneration
J. Neurosci., July 18, 2007; 27(29): 7663 - 7672.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. A. Goodfellow, T. Bowes, K. Sheikh, M. Odaka, S. K. Halstead, P. D. Humphreys, E. R. Wagner, N. Yuki, K. Furukawa, K. Furukawa, et al.
Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy
J. Neurosci., February 16, 2005; 25(7): 1620 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
S. K. Halstead, G. M. O'Hanlon, P. D. Humphreys, D. B. Morrison, B. P. Morgan, A. J. Todd, J. J. Plomp, and H. J. Willison
Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy
Brain, September 1, 2004; 127(9): 2109 - 2123.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.